Published in Small on June 21, 2010
Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res (2011) 1.45
Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small (2010) 1.19
Near-infrared imaging method for the in vivo assessment of the biodistribution of nanoporous silicon particles. Mol Imaging (2011) 1.04
The shape of things to come: importance of design in nanotechnology for drug delivery. Ther Deliv (2012) 1.03
Short and long term, in vitro and in vivo correlations of cellular and tissue responses to mesoporous silicon nanovectors. Small (2012) 0.95
Particle platforms for cancer immunotherapy. Int J Nanomedicine (2013) 0.93
pH-Operated mechanized porous silicon nanoparticles. J Am Chem Soc (2011) 0.93
Proteomic analysis of serum opsonins impacting biodistribution and cellular association of porous silicon microparticles. Mol Imaging (2011) 0.92
Silicon micro- and nanofabrication for medicine. Adv Healthc Mater (2013) 0.90
Biocompatibility assessment of Si-based nano- and micro-particles. Adv Drug Deliv Rev (2012) 0.87
Evaluation of cell function upon nanovector internalization. Small (2012) 0.87
Multifunctional to multistage delivery systems: The evolution of nanoparticles for biomedical applications. Chin Sci Bull (2012) 0.83
Porous silicon advances in drug delivery and immunotherapy. Curr Opin Pharmacol (2013) 0.81
Multivalent presentation of MPL by porous silicon microparticles favors T helper 1 polarization enhancing the anti-tumor efficacy of doxorubicin nanoliposomes. PLoS One (2014) 0.81
Characterization of Free and Porous Silicon-Encapsulated Superparamagnetic Iron Oxide Nanoparticles as Platforms for the Development of Theranostic Vaccines. Med Sci (Basel) (2014) 0.80
Bacteriophage Associated Silicon Particles: Design and Characterization of a Novel Theranostic Vector with Improved Payload Carrying Potential. J Mater Chem B Mater Biol Med (2013) 0.80
Mesoporous silicon microparticles enhance MHC class I cross-antigen presentation by human dendritic cells. Clin Dev Immunol (2013) 0.80
Internalization of red blood cell-mimicking hydrogel capsules with pH-triggered shape responses. ACS Nano (2014) 0.79
Multistage Delivery Technologies: Multifunctional, Interdisciplinary Approaches to Nanomedicine. Mol Ther (2016) 0.77
Enhanced gene delivery in porcine vasculature tissue following incorporation of adeno-associated virus nanoparticles into porous silicon microparticles. J Control Release (2014) 0.77
Variable blocking temperature of a porous silicon/Fe3O4 composite due to different interactions of the magnetic nanoparticles. Nanoscale Res Lett (2012) 0.76
The Emerging Role of Nanotechnology in Cell and Organ Transplantation. Transplantation (2016) 0.75
Preparation, characterization, and cellular associations of silicon logic-embedded vectors. Methods Enzymol (2012) 0.75
Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science (2009) 10.47
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A (2008) 3.80
Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol (2008) 3.78
Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol (1989) 3.59
Intravascular delivery of particulate systems: does geometry really matter? Pharm Res (2008) 3.13
Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol (2008) 2.97
Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol (2002) 2.06
A theoretical model for the margination of particles within blood vessels. Ann Biomed Eng (2005) 1.97
Delivery of nanogram payloads using magnetic porous silicon microcarriers. Lab Chip (2006) 1.93
Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev (2004) 1.90
Detection and quantification of magnetically labeled cells by cellular MRI. Eur J Radiol (2008) 1.87
Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials (2007) 1.72
Tailored porous silicon microparticles: fabrication and properties. Chemphyschem (2010) 1.71
Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. Biomaterials (2005) 1.69
The receptor-mediated endocytosis of nonspherical particles. Biophys J (2008) 1.68
The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials (2009) 1.63
Integrin (alpha v beta 3)-ligand interaction. Identification of a heterodimeric RGD binding site on the vitronectin receptor. J Biol Chem (1990) 1.52
Mitotic trafficking of silicon microparticles. Nanoscale (2009) 1.35
Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS One (2009) 1.31
Molecular assemblies and membrane domains in multivesicular endosome dynamics. Exp Cell Res (2008) 1.18
Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging. Mol Imaging (2007) 1.12
Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies. J Thorac Oncol (2008) 1.07
A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol (1990) 1.06
Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst (1990) 0.98
MR imaging of splenic metastases: ferrite-enhanced detection in rats. AJR Am J Roentgenol (1987) 0.96
Ferrite particles: a new magnetic resonance imaging contrast agent. Lack of acute or chronic hepatotoxicity after intravenous administration. J Lab Clin Med (1987) 0.94
Vapor-phase self-assembled monolayers of aminosilane on plasma-activated silicon substrates. J Colloid Interface Sci (2008) 0.94
Digital microfluidics and delivery of molecular payloads with magnetic porous silicon chaperones. Dalton Trans (2007) 0.89
Selection of thioaptamers for diagnostics and therapeutics. Ann N Y Acad Sci (2006) 0.89
Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study. Ann Oncol (2007) 0.89
Physical state of poorly water soluble therapeutic molecules loaded into SBA-15 ordered mesoporous silica carriers: a case study with itraconazole and ibuprofen. Langmuir (2008) 0.88
Optical spectra of a novel polyoxometalate occluded within modified MCM-41. J Phys Chem B (2005) 0.80
Polyoxomolybdate-stabilized Ru(0) nanoparticles deposited on mesoporous silica as catalysts for aromatic hydrogenation. Chemphyschem (2007) 0.79
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol (2008) 3.78
Intravascular delivery of particulate systems: does geometry really matter? Pharm Res (2008) 3.13
Clinical proteomics: written in blood. Nature (2003) 2.81
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Nanotechnologies for biomolecular detection and medical diagnostics. Curr Opin Chem Biol (2006) 2.74
Seven challenges for nanomedicine. Nat Nanotechnol (2008) 2.59
Both cultured and freshly isolated adipose tissue-derived stem cells enhance cardiac function after acute myocardial infarction. Eur Heart J (2009) 2.21
Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol (2010) 2.17
Three-dimensional tissue culture based on magnetic cell levitation. Nat Nanotechnol (2010) 2.11
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85
Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials (2007) 1.72
Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release (2011) 1.72
Tailored porous silicon microparticles: fabrication and properties. Chemphyschem (2010) 1.71
Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med (2013) 1.69
Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology (2009) 1.63
The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials (2009) 1.63
What does physics have to do with cancer? Nat Rev Cancer (2011) 1.59
Morphologic instability and cancer invasion. Clin Cancer Res (2005) 1.55
Nanogeometry: beyond drug delivery. Nat Nanotechnol (2008) 1.54
Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res (2009) 1.53
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One (2010) 1.49
Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol (2008) 1.48
Osmotic pressure beyond concentration restrictions. J Phys Chem B (2007) 1.46
Biotechnology apprenticeship for secondary-level students: teaching advanced cell culture techniques for research. Cell Biol Educ (2002) 1.45
Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res (2011) 1.45
Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells. Cell Biochem Funct (2012) 1.44
T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A (2003) 1.37
Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv (2007) 1.36
Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv (2012) 1.35
Mitotic trafficking of silicon microparticles. Nanoscale (2009) 1.35
Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice. Adv Funct Mater (2012) 1.35
MR thermometry-based feedback control of laser interstitial thermal therapy at 980 nm. Lasers Surg Med (2004) 1.35
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest (2007) 1.34
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Modulation of syndecan-1 shedding after hemorrhagic shock and resuscitation. PLoS One (2011) 1.32
Biodegradable porous silicon barcode nanowires with defined geometry. Adv Funct Mater (2010) 1.31
Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res A (2010) 1.31
Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev Anticancer Ther (2006) 1.30
Multiparameter computational modeling of tumor invasion. Cancer Res (2009) 1.28
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci (2011) 1.27
Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action. Circ Res (2010) 1.26
Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest (2014) 1.26
The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials (2012) 1.25
Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest (2010) 1.25
Interstitial stress and fluid pressure within a growing tumor. Ann Biomed Eng (2003) 1.25
Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta (2010) 1.23
Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci (2010) 1.22
Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest (2011) 1.21
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res (2013) 1.21
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther (2010) 1.20
Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small (2010) 1.19
Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One (2010) 1.19
Biomedical applications of functionalized fullerene-based nanomaterials. Int J Nanomedicine (2009) 1.19
Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater (2011) 1.16
Quantitative mechanics of endothelial phagocytosis of silicon microparticles. Cytometry A (2009) 1.16
Tailoring of the nanotexture of mesoporous silica films and their functionalized derivatives for selectively harvesting low molecular weight protein. ACS Nano (2010) 1.16
Design of bio-mimetic particles with enhanced vascular interaction. J Biomech (2009) 1.15
Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale (2010) 1.15
Laparoscopic treatment of splenic artery aneurysms. J Vasc Surg (2009) 1.13
Wireless self-gated multiple-mouse cardiac cine MRI. Magn Reson Med (2008) 1.12
E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv Mater (2011) 1.12
Development of a macromolecular dual-modality MR-optical imaging for sentinel lymph node mapping. Invest Radiol (2007) 1.12
Nanotechnology for breast cancer therapy. Biomed Microdevices (2009) 1.10
Mesoporous silica chips for selective enrichment and stabilization of low molecular weight proteome. Proteomics (2010) 1.08
Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservation. Biomaterials (2012) 1.07
Human lung cancer cells grown in an ex vivo 3D lung model produce matrix metalloproteinases not produced in 2D culture. PLoS One (2012) 1.07
The transport of nanoparticles in blood vessels: the effect of vessel permeability and blood rheology. Ann Biomed Eng (2008) 1.07
Glycolytic inhibition alters anaplastic thyroid carcinoma tumor metabolism and improves response to conventional chemotherapy and radiation. Mol Cancer Ther (2012) 1.06
Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Lett (2012) 1.06
Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget (2011) 1.06
Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small (2013) 1.05
Near-infrared imaging method for the in vivo assessment of the biodistribution of nanoporous silicon particles. Mol Imaging (2011) 1.04
Nanotechnology and tumor imaging: seizing an opportunity. Mol Imaging (2004) 1.04